Jhan Jhen-Hao, Yang Yuan-Han, Chang Yu-Han, Guu Shiao-Jin, Tsai Chia-Chun
a Department of Urology , School of Medicine, College of Medicine, Kaohsiung Medical University , Kaohsiung , Taiwan.
b Department of Urology , Kaohsiung Medical University Hospital , Kaohsiung , Taiwan.
Aging Male. 2017 Mar;20(1):33-38. doi: 10.1080/13685538.2016.1271782. Epub 2017 Jan 9.
Androgen-deprivation therapy (ADT) is recognized to be the preferred first-line treatment for advanced prostate cancer. However, the risk-benefit ratio of ADT remains poorly defined and the relationship between androgen depletion and dementia is not clear.
To investigate the risk of developing Alzheimer's disease (AD) in patients undergoing ADT for prostate cancer.
Data from 24 360 prostate cancer patients were collected from the Longitudinal Health Insurance Database of Taiwan. In total, 15 959 patients who underwent ADT were included in the study cohort, and another 8401 patients who did not receive ADT were included as a non-ADT cohort.
During the average 4-year follow-up period, the incidence of AD was 2.78 per 1000 person-years in the non-ADT cohort and 5.66 per 1000 person-years in the ADT cohort. After adjusting for age and all comorbidities, the combined ADT cohort was found to be 1.84 times more likely to develop AD than the non-ADT control group (95%CI 1.33-2.55, p < 0.001).
The present results suggest that ADT use is associated with an increased risk of developing AD.
雄激素剥夺疗法(ADT)被认为是晚期前列腺癌的首选一线治疗方法。然而,ADT的风险效益比仍不明确,雄激素耗竭与痴呆之间的关系也不清楚。
研究接受前列腺癌ADT治疗的患者患阿尔茨海默病(AD)的风险。
从台湾纵向健康保险数据库收集了24360例前列腺癌患者的数据。总共15959例接受ADT治疗的患者被纳入研究队列,另外8401例未接受ADT治疗的患者被纳入非ADT队列。
在平均4年的随访期内,非ADT队列中AD的发病率为每1000人年2.78例,ADT队列中为每1000人年5.66例。在调整年龄和所有合并症后,发现联合ADT队列患AD的可能性是非ADT对照组的1.84倍(95%CI 1.33 - 2.55,p < 0.001)。
目前的结果表明,使用ADT与患AD的风险增加有关。